TickerTalks
Browse all tickers →
TickerTalks›$SDEV
SDSDEV

Stablecoin Development Corp.

$SDEV·$52M·Medical - Pharmaceuticals·Healthcare
——
SDSDEV
$SDEVStablecoin Development Corp.
——0 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $SDEV on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

0X posts · last 7 days
No mention history yet

What it does

Plain-English summary of the business — what they sell and how they make money.

Stablecoin Development Corp. specializes in manufacturing and distributing eye and skin health solutions that have undergone rigorous scientific development and proven efficacy in clinical settings. Their product portfolio features prominent brands such as Avenova, NeutroPhase, and DERMAdoctor. This enterprise was established on January 19, 2000, and its main office is situated in Emeryville, California.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Pharmaceuticals sits in its cycle right now — and what that implies for $SDEV.

Medical - Pharmaceuticals · Healthcare

Royalty Pharma took a ~$3/share hit on Novartis pelacarsen Phase 3 failure, a near-term setback to its lipoprotein(a) royalty stream. Liquidia's YUTREPIA patent litigation against UTC remains the key binary catalyst. Niche specialty pharma with established reimbursement (Corcept, Kiniksa) is the defensive sub-segment.

Industry benchmark

5-name peer basket
+70.2%YTD
+57.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
0.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-5.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-141%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-22.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
11.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
7.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
99.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$0.01$-0.55+101.8%
Q1 2026May 15, 2026$0.10$-1.00+110.0%
Q3 2025Nov 7, 2025$-1.15$-1.05-9.5%
Q2 2025Aug 14, 2025$-1.65$-1.05-57.1%
Next earningsThu, Nov 5·consensus EPS $-0.60

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$2.2M—100%-146%$-1.32$-6.0M
Q1 FY26$2.5M—100%-15.6%$21.23$-1.8M
Q4 FY25$-521K—17.1%350%$-4.57$-2.3M
Q3 FY25$521K—8.1%-224%$-1.10$-1.8M

Forward consensus

1-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$15.8M$15.8M – $15.8M-$1.90-$1.90 – -$1.901

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.3.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+0.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 22.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today13.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.095-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 15Kazley Michael JohnCEO24.7K sh$27KSellJun 15Ventures Iv Framework10% owner24.7K sh$27KSellJun 15Fund Lp R0110% owner24.7K sh$27K
+ 8 other (5 awards · 3 inthemoneys) in window

See when $SDEV insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Stablecoin Development (NYSEAMERICAN:SDEV) Stock Price Passes Below 200 Day Moving Average – What’s Next?defenseworld.net·36d agoSDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholdersglobenewswire.com·47d agoStablecoin Development Corporation Reports Second Quarter 2026 Financial Resultsglobenewswire.com·50d ago

In themes

Explore the broader themes this ticker is being talked about under.

Crypto Equity PlaysStablecoins & Tokenization

More in Medical - Pharmaceuticals

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LQDA$CORT$PAVS$RPRX$KNSA
Voices on X · last 7 days

No standout posts about $SDEV on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport